Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

Professor Virginia Harrison, EGFR Positive UK, said ... 95% CI 0.57-0.97, maturity 41%), with consistent results across all prespecified subgroups. The trial will continue to assess OS as ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Weight fluctuation was associated with a greater risk for diabetic kidney disease progression among individuals with type 1 diabetes.

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from Buy to Neutral. Analyst Price Forecast Suggests 207.54% Upside As ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared ...